KYORIN Pharmaceutical Co., Ltd. Logo

KYORIN Pharmaceutical Co., Ltd.

Researches, develops, and sells a portfolio of ethical, generic, and OTC medicines.

4569 | T

Overview

Corporate Details

ISIN(s):
JP3247090008
LEI:
Country:
Japan
Address:
千代田区大手町一丁目3番7号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

KYORIN Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company engaged in the research, development, manufacturing, and commercialization of medicines. The company's business focuses on several key areas, including the creation of innovative new ethical drugs through its own drug discovery and in-licensing activities. Its portfolio also encompasses generic drugs and over-the-counter (OTC) products, such as the COOL ONE series. The company aims to contribute to public health by developing high-value treatments that meet medical needs. In April 2023, the current entity was formed when KYORIN Holdings, Inc. merged with its wholly-owned subsidiary, KYORIN Pharmaceutical Co., Ltd., and adopted the subsidiary's name.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-13 07:42
Interim Report
確認書
Japanese 8.9 KB
2025-11-13 07:36
Interim Report
半期報告書-第68期(2025/04/01-2025/09/30)
Japanese 220.9 KB
2025-06-26 07:25
Post-Annual General Meeting Information
臨時報告書
Japanese 23.5 KB
2025-06-19 08:55
Governance Information
内部統制報告書-第67期(2024/04/01-2025/03/31)
Japanese 27.1 KB
2025-06-19 08:53
Registration Form
確認書
Japanese 8.9 KB
2025-06-19 08:50
Registration Form
有価証券報告書-第67期(2024/04/01-2025/03/31)
Japanese 1.4 MB
2024-11-13 07:27
Interim Report
確認書
Japanese 8.9 KB
2024-11-13 07:24
Interim Report
半期報告書-第67期(2024/04/01-2025/03/31)
Japanese 216.2 KB
2024-06-28 08:30
Post-Annual General Meeting Information
臨時報告書
Japanese 23.5 KB
2024-06-24 08:53
Governance Information
内部統制報告書-第66期(2023/04/01-2024/03/31)
Japanese 24.3 KB
2024-06-24 08:51
Registration Form
確認書
Japanese 8.9 KB
2024-06-24 08:47
Registration Form
有価証券報告書-第66期(2023/04/01-2024/03/31)
Japanese 1.3 MB
2024-02-14 07:07
Quarterly Report
確認書
Japanese 8.9 KB
2024-02-14 07:05
Quarterly Report
四半期報告書-第66期第3四半期(2023/10/01-2023/12/31)
Japanese 190.9 KB
2023-11-14 07:36
Report Publication Announcement
確認書
Japanese 8.2 KB

Automate Your Workflow. Get a real-time feed of all KYORIN Pharmaceutical Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for KYORIN Pharmaceutical Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for KYORIN Pharmaceutical Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

NKMAX Co., Ltd. Logo
Biotech firm for NK cell therapies, global research reagents, diagnostics, and supplements.
South Korea
182400
NLS Pharmaceutics Ltd. Logo
Developing therapies for rare CNS disorders, specializing in narcolepsy and sleep-wake issues.
United States of America
NLSP
NovaBay Pharmaceuticals, Inc. Logo
Develops clinically-proven anti-infective therapies for eyecare, skincare, and wound care.
United States of America
NBY
Novacyt Logo
Designs and supplies molecular diagnostic tests and PCR kits for human, veterinary, and food safety.
France
ALNOV
Novartis AG Logo
Develops and markets innovative medicines globally using advanced science and technology.
Switzerland
NOVN
NOVAVAX INC Logo
Develops and commercializes nanoparticle vaccines for serious infectious diseases.
United States of America
NVAX
Develops first-in-class drugs and supplements for metabolic and fibrotic diseases.
South Korea
229500
Novo Nordisk Logo
Develops medicines and devices for chronic diseases like diabetes, obesity, and rare disorders.
Denmark
NOVO
NRX Pharmaceuticals, Inc. Logo
Develops novel oral drugs for CNS disorders, targeting suicidal depression and PTSD.
United States of America
NRXP
NuCana plc Logo
Develops safer anti-cancer medicines with ProTide technology to overcome cell resistance.
United States of America
NCNA

Talk to a Data Expert

Have a question? We'll get back to you promptly.